Table 1.
Prognostic parameters in total BC sample and in aggressive subtypes.
| Prognostic parameters | Total BC | LB | HER2+ | TN | |
|---|---|---|---|---|---|
| Tumor size | <1.5 cm | 10 (8.9%) | 3 (8.3%) | 2 (8.7%) | 5 (9.4%) |
| 1.5–3.0 cm | 57 (50.9%) | 23 (63.9%) | 14 (60.9%) | 20 (37.8%) | |
| >3.0 cm | 45 (40.2%) | 10 (27.8%) | 7 (30.4%) | 28 (52.8%) | |
|
| |||||
| TNM staging | I | 19 (18.1%) | 7 (20%) | 5 (19.2%) | 7 (15.9%) |
| II | 39 (37.2%) | 14 (40%) | 8 (30.8%) | 17 (38.6%) | |
| III | 37 (35.2%) | 12 (34.3%) | 9 (34.6%) | 16 (36.4%) | |
| IV | 10 (9.5%) | 2 (5.7%) | 4 (15.4%) | 4 (9.1%) | |
|
| |||||
| Histological grade | II | 30 (26.8%) | 12 (33.3%) | 8 (34.8%) | 10 (18.9%) |
| III | 82 (73.2%) | 24 (66.7%) | 15 (65.2%) | 43 (81.1%) | |
|
| |||||
| Ki-67 | Low | 7 (8.8%) | 4 (19.0%) | 0 (0.0%) | 3 (7.3%) |
| Moderate | 25 (31.2%) | 9 (42.9%) | 7 (46.7%) | 9 (23.6%) | |
| High | 48 (60.0%) | 8 (38.1%) | 8 (53.3%) | 32 (69.1%) | |
|
| |||||
| Lymph nodes commitment | No | 54 (49.1%) | 19 (52.8%) | 12 (52.2%) | 23 (45.1%) |
| Yes | 56 (50.9%) | 17 (47.2%) | 11 (47.8%) | 28 (54.9%) | |
LB: Luminal B HER+; HER2+: HER2-enriched; TN: triple-negative.